A New Era in Recurrent LGSOC: Incorporating Approved Therapies, Biomarkers, and Clinical Strategies
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
A New Era in Recurrent LGSOC: Incorporating Approved Therapies, Biomarkers, and Clinical Strategies
-
ナレーター：
-
著者：
This symposium will explore the rapidly evolving landscape of treatment for recurrent low-grade serous ovarian cancer (LGSOC), with a focus on newly FDA-approved therapies and investigational strategies, MEC Inhibitors, CDK46 Inhibitors, hormonal treatments and other opportunities in the competitive landscape. LGSOC remains a challenging subtype due to its unique biology and resistance to conventional therapies. Faculty will examine recent clinical trial data, discuss emerging best practices for biomarker testing and sequencing, and explore practical considerations for managing side effects and ensuring patient access to innovative treatments. Through real-world cases and interactive discussion, participants will gain insights to personalize care and optimize outcomes for patients living with recurrent LGSOC.